Positive news from portfolio company Oxford BioTherapeutics – it has announced today that it has achieved another milestone with Boehringer Ingelheim for the progress of a second oncology drug candidate.
Positive news from portfolio company Oxford BioTherapeutics – it has announced today that it has achieved another milestone with Boehringer Ingelheim for the progress of a second oncology drug candidate.
Estimated reading time: 2 min
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
If you are interested in learning more about how to protect yourself, visit the FCA’s website here.